Mekelle University College of Health Sciences, Mekelle, Ethiopia.
Hayat General Hospital, Addis Ababa, Ethiopia.
PLoS One. 2020 Oct 22;15(10):e0240880. doi: 10.1371/journal.pone.0240880. eCollection 2020.
There is very little data on long-term immune recovery responses in patients on suppressive antiretroviral therapy (ART) in the setting of sub-Saharan Africa (SSA). Thus, we sought to determine CD4+ T-cell, CD8+ T-cell and CD4/CD8 ratio responses in a cohort of HIV infected individuals on sustained suppressive ART followed up for more than a decade.
The cohort comprised adult patients who started ART between 2001 and 2007 and followed for up to 14 years. Trends in median CD4+ T-cells, CD8+ T-cells and CD4/CD8 ratio were reviewed retrospectively. Poisson regression models were used to identify factors associated with achieving normalized T-cell biomarkers. Kaplan-Meier curves were used to estimate the probability of attaining normalized counts while on suppressive ART.
A total of 227 patients with a median duration of follow-up on ART of 12 (IQR: 10.5-13.0) years were included. CD4 cell count increased from baseline median of 138 cells (IQR: 70-202) to 555 cells (IQR: 417-830). CD4 cell increased continuously up until 5 years, after which it plateaued up until 14 years of follow up. Only 69.6% normalized their CD4 cell count within a median of 6.5 (IQR: 3.0-10.5) years. In addition, only 15.9% of the cohort were able to achieve the median reference CD4+ T-cell threshold count in Ethiopians (≈760 cells/μL). CD8+ T-cell counts increased initially until year 1, after which continuous decrease was ascertained. CD4/CD8 ratio trend revealed continuous increase throughout the course of ART, and increased from a median baseline of 0.14 (IQR: 0.09-0.22) to a median of 0.70 (IQR: 0.42-0.95). However, only 12.3% normalized their ratio (≥ 1.0) after a median of 11.5 years. In addition, only 8.8% of the cohort were able to achieve the median reference ratio of healthy Ethiopians.
Determination of both CD4+ and CD8+ T-cells, along with CD4/CD8 ratio is highly relevant in long-term follow-up of patients to assess immune recovery. Monitoring ratio levels may serve as a better biomarker risk for disease progression among patients on long-term ART. In addition, the findings emphasize the relevance of initiation of ART at the early stage of HIV-1 infection.
在撒哈拉以南非洲(SSA)地区,接受抑制性抗逆转录病毒疗法(ART)的患者的长期免疫恢复反应数据很少。因此,我们试图确定在接受持续抑制性 ART 治疗并随访超过十年的 HIV 感染个体中 CD4+T 细胞、CD8+T 细胞和 CD4/CD8 比值的反应。
该队列包括 2001 年至 2007 年期间开始接受 ART 的成年患者,并随访了长达 14 年。回顾性审查了中位数 CD4+T 细胞、CD8+T 细胞和 CD4/CD8 比值的趋势。使用泊松回归模型确定与实现正常化 T 细胞生物标志物相关的因素。使用 Kaplan-Meier 曲线估计在抑制性 ART 期间达到正常计数的概率。
共纳入 227 名中位 ART 随访时间为 12 年(IQR:10.5-13.0)的患者。CD4 细胞计数从基线中位数 138 个细胞(IQR:70-202)增加到 555 个细胞(IQR:417-830)。CD4 细胞持续增加,直到 5 年,之后在 14 年的随访中达到平台期。中位数为 6.5 年(IQR:3.0-10.5),只有 69.6%的患者能够使 CD4 细胞计数正常化。此外,该队列中只有 15.9%的人能够达到埃塞俄比亚人的中位数参考 CD4+T 细胞阈值计数(≈760 个细胞/μL)。CD8+T 细胞计数最初增加,直到第 1 年,然后确定连续下降。CD4/CD8 比值趋势显示在整个 ART 过程中持续增加,并从基线中位数 0.14(IQR:0.09-0.22)增加到中位数 0.70(IQR:0.42-0.95)。然而,中位数为 11.5 年后,只有 12.3%的患者使比值正常化(≥1.0)。此外,该队列中只有 8.8%的人能够达到健康埃塞俄比亚人的中位数比值。
在长期随访患者时,确定 CD4+和 CD8+T 细胞以及 CD4/CD8 比值对于评估免疫恢复非常重要。监测比值水平可能是长期接受 ART 的患者疾病进展的更好生物标志物风险。此外,这些发现强调了在 HIV-1 感染早期开始 ART 的相关性。